Abstract
The design and synthesis of safe efficient non-viral vectors for gene delivery has attracted significant attention in recent years due primarily to the severe side-effect profile reported with the use of their viral counterparts. Previous experiments have revealed that the strong interaction between the carriers and nucleic acid may well hinder the release of the gene from the complex in the cytosol adversely affecting transfection efficiency. However, incorporating reducible disulfide bonds within the delivery systems themselves which are then cleaved in the glutathione-rich intracellular environment may help in solving this puzzle. This review focuses on recent development of these reducible carriers. The biological rationale and approaches to the synthesis of reducible vectors are discussed in detail. The in vitro and in vivo evaluations of reducible carriers are also summarized and it is evident that they offer a promising approach in non-viral gene delivery system design.
Keywords: Disulphide bond, reducible vector, non-viral vector, gene delivery
Mini-Reviews in Medicinal Chemistry
Title: Reducible Disulfide-Based Non-Viral Gene Delivery Systems
Volume: 9 Issue: 10
Author(s): Defang Ouyang, Neha Shah, Hong Zhang, Sean C. Smith and Harendra S. Parekh
Affiliation:
Keywords: Disulphide bond, reducible vector, non-viral vector, gene delivery
Abstract: The design and synthesis of safe efficient non-viral vectors for gene delivery has attracted significant attention in recent years due primarily to the severe side-effect profile reported with the use of their viral counterparts. Previous experiments have revealed that the strong interaction between the carriers and nucleic acid may well hinder the release of the gene from the complex in the cytosol adversely affecting transfection efficiency. However, incorporating reducible disulfide bonds within the delivery systems themselves which are then cleaved in the glutathione-rich intracellular environment may help in solving this puzzle. This review focuses on recent development of these reducible carriers. The biological rationale and approaches to the synthesis of reducible vectors are discussed in detail. The in vitro and in vivo evaluations of reducible carriers are also summarized and it is evident that they offer a promising approach in non-viral gene delivery system design.
Export Options
About this article
Cite this article as:
Ouyang Defang, Shah Neha, Zhang Hong, Smith C. Sean and Parekh S. Harendra, Reducible Disulfide-Based Non-Viral Gene Delivery Systems, Mini-Reviews in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/138955709789055225
DOI https://dx.doi.org/10.2174/138955709789055225 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Challenges of Stem-cell-based Craniofacial Regeneration
Current Stem Cell Research & Therapy Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design 3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy
Current Pharmaceutical Design Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Subject Index to Volume 5
Current Genomics Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Cervical Cancer Prevention: More than Just a Pap in a Diverse Urban Community
Current Women`s Health Reviews Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice
Current Pharmaceutical Biotechnology Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Wealth of Opportunity - The C1 Domain as a Target for Drug Development
Current Drug Targets Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry